Hospitals are ditching their reliance on Intuitive Surgical’s da Vinci platform, and they finally have real alternatives. After two decades of near-total market dominance, Intuitive now faces genuine competition from FDA-cleared platforms like Medtronic’s Hugo and CMR Surgical’s Versius, along with Johnson & Johnson’s Ottava system in the pipeline. This fragmentation is forcing hospital systems to make genuine platform decisions rather than defaulting to the established player—and many are choosing to deploy multiple robots across their facilities instead of standardizing on one. The surgical robotics market is growing faster than the platforms themselves can launch. North America accounted for 50.6% of global robot-assisted procedures in 2025, with the U.S. hospital market valued at $11.07 billion.
But the real story isn’t just scale—it’s choice. Medical City hospitals in the Dallas-Fort Worth area, for instance, expanded their surgical robotics footprint in February 2026 by adding both da Vinci 5 and Mako systems, reflecting a deliberate multi-platform strategy rather than monoculture deployment. That pattern is becoming the standard as hospitals evaluate systems based on surgical specialty, console design, price models, and space constraints rather than brand loyalty. A fundamental shift is also happening in how hospitals acquire these systems. Robotics-as-a-Service models, which convert capital expenditure into operational expense, are projected to grow at 30% annually through 2033—faster than any other adoption model. This matters most to mid-market hospitals and ambulatory surgery centers that lack the $1M+ upfront budgets for traditional purchase agreements.
Table of Contents
- Why Hospitals Are Breaking Free from da Vinci Dependency
- New Platforms Arriving (and More in the Pipeline)
- Market Size and Regional Divergence
- Why RaaS Is Reshaping Hospital Purchasing
- Urology Dominance and Orthopedic Acceleration
- Hospital Multi-Platform Deployment Examples
- Competitive Pressure and Market Fragmenting
Why Hospitals Are Breaking Free from da Vinci Dependency
Intuitive Surgical’s monopoly ended not because the da Vinci stopped working, but because competing platforms finally proved equivalent in clinical outcomes while offering practical advantages. Medtronic’s Hugo received FDA 510(k) clearance for urologic procedures in December 2025, with a clinical cohort of 137 patients demonstrating safety across prostatectomy, nephrectomy, and cystectomy procedures. That wasn’t a breakthrough—it was validation that another company could clear the regulatory bar. CMR Surgical followed weeks later with FDA clearance for Versius Plus in cholecystectomy, with U.S. market rollout scheduled for 2026. What makes these platforms defensible is design philosophy. Hugo and Versius both use mobile cart-based systems with open console configurations, giving operating rooms far more layout flexibility than da Vinci’s fixed tower footprint.
A surgeon can reposition the console mid-procedure or set it aside entirely for hybrid open-robotic approaches. For hospital administrators running tight OR schedules, that flexibility justifies the platform switch. CMR’s Versius has already gained traction in UK NHS hospitals and is expanding in India, Europe, and Latin America before even launching in the U.S., signaling that hospitals internationally view it as a genuine alternative rather than a novelty system. The monopoly break is also creating pricing pressure. When one company controls an entire market, negotiating leverage defaults to the incumbent. Now when a hospital upgrades its robotic suite, it’s comparing total cost of ownership across three or four platforms instead of accepting Intuitive’s terms. That competition is filtering down to service contracts, training programs, and procedure kits—all historically locked behind high markups.
New Platforms Arriving (and More in the Pipeline)
Medtronic’s Hugo RAS system represents the most credible challenge to Intuitive’s urology franchise. The December 2025 FDA clearance was not surprise—Medtronic telegraphed this for years—but the 137-patient premarket approval cohort suggests the company did not rush through approval. Medtronic has also publicly committed to general surgery and gynecology indications for 2026, meaning Hugo’s addressable market will triple beyond urology alone. If those submissions hit their timeline, surgeons by late 2026 will have three distinct platforms available for common procedures like hysterectomies and cholecystectomy. CMR Surgical’s Versius Plus focuses narrowly on gallbladder removal as its FDA-cleared indication, which seems restrictive until you recognize that cholecystectomy is one of the highest-volume robotic procedures performed globally. CMR is betting that hospital systems will adopt Versius for high-volume specialty centers and let it expand from there. The modular design—no fixed tower, minimal setup time—makes this strategy plausible.
A surgical center performing 500+ cholecystectomies annually gains enormous scheduling flexibility if it can roll the robot in and out of the OR between cases instead of occupying a dedicated robotic suite. Johnson & Johnson’s Ottava system represents the wild card. J&J’s submission to the FDA was originally expected in 2025 but has slipped into early 2026, giving competitors a longer runway. When Ottava clears—and most observers assume it will—J&J will leverage existing relationships with hospital systems and surgical supply chains. J&J’s advantage is not technical; it’s that hospitals already buy massive volumes of instruments, implants, and consumables from the company. Integration of a J&J-branded robot into existing purchasing workflows removes friction at the administrative level. Asensus Surgical’s Senhance system also remains in the market, though it has captured only niche adoption. The competitive field is crowded now, not because every system is equally capable, but because enough platforms have crossed the FDA approval threshold that hospitals face real choice.
Market Size and Regional Divergence
The surgical robotics market is projected to grow from $11.07 billion in 2025 to $39.42 billion by 2033, a 17.3% compound annual growth rate. That trajectory assumes sustained adoption across most surgical specialties and geographies. North America will remain the largest market in absolute terms, but Asia-Pacific is the fastest-growing region. China, India, Japan, and South Korea are all accelerating adoption, driven by both healthcare infrastructure investment and the cost-effectiveness of newer modular platforms like Versius and Hugo compared to da Vinci’s capital requirements. The regional divergence has real implications for hospital purchasing. A system in tier-2 Indian cities can now evaluate robots without assuming they must choose the expensive, feature-rich da Vinci. CMR’s Versius is explicitly targeting this segment—it’s already in use at NHS hospitals in the United Kingdom and is expanding in Latin America.
When new platforms achieve cost parity or offer operational advantages (smaller footprint, faster setup, RaaS availability), they capture market share fastest in price-sensitive regions first, then filter up to premium markets. North America’s 50.6% share of global procedures in 2025 is also misleading if interpreted as saturation. The U.S. market remains heavily concentrated in tertiary academic centers and large health systems. Mid-size hospitals and ambulatory surgery centers perform only a fraction of the robot-assisted procedures they could. The RaaS model—still embryonic—is specifically designed to unlock that tail. Projections showing 30% annual growth for RaaS through 2033 assume this segment will grow 2-3x faster than traditional capital-purchase models.
Why RaaS Is Reshaping Hospital Purchasing
Robotics-as-a-Service flips the capital expenditure problem on its head. A $1.5M upfront system cost becomes a per-procedure fee or monthly service charge. For an ambulatory surgery center performing 100 robotic procedures yearly, the operational model is fundamentally different from a 500-procedure academic hospital. RaaS lets smaller facilities participate in robotic surgery without financing constraints that force them to underutilize equipment to justify capital investment. The catch is that RaaS only works if the service provider (whether a robot manufacturer, hospital network, or third-party operator) can aggregate enough procedures to absorb operational costs.
If a single facility cannot drive volume, the RaaS payment per procedure climbs—potentially higher than purchase-based depreciation. This creates a hidden market threshold: below roughly 150-200 procedures annually, RaaS has to offer dramatic administrative simplicity or flexibility to compete with purchase models. Above that volume, pure RaaS economics favor the operator over capital purchase. CMR Surgical and Medtronic are both positioning for RaaS expansion, though neither has published definitive pricing. The competitive advantage will accrue to whoever can operate a distributed fleet efficiently—ensuring equipment utilization across multiple surgical centers, minimizing downtime, and absorbing training and maintenance into the service fee. Hospital systems considering robotics need to map their actual procedure volume and specialty mix against both capital and RaaS scenarios; the correct choice depends on local demand, not global averages.
Urology Dominance and Orthopedic Acceleration
Urology remains the anchor surgical specialty for robot-assisted procedures, accounting for 27.78% of market share in 2025. Prostatectomy, nephrectomy, and cystectomy are high-volume procedures, and Intuitive’s da Vinci has decades of validation in these cases. Medtronic’s Hugo urology clearance was therefore strategic—it enters the largest single-specialty market. But urology’s dominance also masks rapid growth elsewhere. Orthopedic and spine surgery is the fastest-expanding indication, with projected growth at 23% compound annual rate through 2033.
The clinical case for robotic assistance in joint replacement and spinal fusion is different than urology—orthopedics benefits from extreme precision in implant positioning and alignment, but the soft-tissue dissection and retraction demands are lower. Mako (owned by Stryker), MAKOplasty, and emerging platforms like J&J’s offerings target this specialty. The shift toward orthopedic robotics also explains why hospitals are deploying multiple systems: a facility with high urology volume (da Vinci or Hugo) and high orthopedic volume (Mako or J&J) cannot standardize on one platform without sacrificing specialization. A practical warning: orthopedic robotics adoption is still accelerating, but regulatory approvals and surgeon comfort are not yet mature. Early-adopter hospitals will see clinical advantages; late-adopters may avoid expensive learning curves. But this specialty divergence is inevitable, and hospitals that plan for single-robot environments risk underutilizing equipment or forcing surgeons into suboptimal workflow constraints.
Hospital Multi-Platform Deployment Examples
Medical City hospitals in Fort Worth and Arlington, Texas exemplify the emerging standard: simultaneous deployment of multiple robotic platforms. In February 2026, the system added da Vinci 5 systems alongside Mako robotic-arm systems. This is not a transition away from da Vinci; it’s a deliberate expansion to support both soft-tissue surgical specialties (urology, general surgery, gynecology) and orthopedic procedures within a single health system.
Multi-platform deployment requires investment in staff training, maintenance contracts, and capital allocation that pure standardization avoids. But it also signals that hospital administrators view robots as specialty-optimized tools, not interchangeable infrastructure. Surgeons in high-volume specialties expect platform-specific training and familiarity; forcing a urology surgeon onto an orthopedic-focused robot creates workflow friction and potential safety risks. The medical economics favor specialization over uniformity.
Competitive Pressure and Market Fragmenting
Constancy Researchers documented that Intuitive Surgical’s roughly two-decade monopoly in soft-tissue surgical robotics is definitively over. Hugo, Versius, Ottava, and Senhance represent genuine competitive entrants with distinct design and positioning strategies. None of these competitors will capture Intuitive’s entire market share—da Vinci systems will remain the installed base for years—but they will fragment the high-margin installed base and constrain Intuitive’s pricing power on new deployments.
The modular platform preference signals a market divergence. Hospitals want mobile carts and open consoles (Hugo, Versius) over fixed towers, prioritizing OR flexibility and faster setup times over other design tradeoffs. This preference has cascading effects: it favors CMR and Medtronic in new procurement rounds and creates switching costs for hospitals invested in traditional fixed-tower configurations. A hospital with three da Vinci towers already installed will not abandon that infrastructure immediately, but they will evaluate alternatives for incremental capacity expansion—and they are likely to choose modular systems that do not require dedicated suite redesign.
